TRANSLATIONAL BIOIMAGING CORE SHARED RESOURCE (TBICSR) In vivo imaging biomarkers have become indispensable in cancer research. The Translational BioImaging Core Shared Resource (TBICSR) provides a variety of imaging resources and support for Fred Hutch/University of Washington Cancer Consortium research through the interdisciplinary operations of shared resources across institutions. The goals of TBICSR are to make the widest range of high-end imaging resources available to Consortium members in a cost effective and efficient manner. TBICSR accopmplishes this by implementing a shared use model of imaging resources (and expertise). This is the most cost-effective way to make a wide range of imaging resources available to Consortium members regardless of usage volume at an individual site. Efficiency in enacting studies is enabled by allowing skilled users to access equipment via on-line scheduling and also by providing consultation services for prospective investigators seeking advice regarding imaging options. When consultation is requested, an imaging specialist is available to assist in Institutional Animal Care and Use Committee (IACUC) writing, arrangement of inter-institutional transportation and housing if needed, and system scheduling. Optimization of imaging resources is further supported through faculty imaging modality experts that engage with investigators that desire their guidance. Imaging equipment available through TBICSR spans the range of magnetic resonance imaging (MRI), positron emission tomography (PET), computed tomography (CT), ultrasound (US), and optical imaging. Finally, TBICSR is supported by staff with greater than 60 years of experience in conducting research imaging studies and in animal handling and management. TBICSR obtained ?Outstanding? ranking in the last CCSG cycle. The strengths of the resource were and continue to be the expertise of its imaging modality leaders and the large variety of specialized major instrumentation available to serve the imaging needs of Cancer Consortium members. In vivo imaging is an invaluable way to non-invasively and longitudinally study the disease process and therapeutic response in animals, which is so vital to Consortium research, prior to human studies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA015704-46
Application #
10125962
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-01-01
Project End
2024-12-31
Budget Start
2021-01-01
Budget End
2021-12-31
Support Year
46
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Cheng, Heather H (2018) The resounding effect of DNA repair deficiency in prostate cancer. Urol Oncol 36:385-388
Poudel, Kumud R; Roh-Johnson, Minna; Su, Allen et al. (2018) Competition between TIAM1 and Membranes Balances Endophilin A3 Activity in Cancer Metastasis. Dev Cell 45:738-752.e6
Holly, Mayumi K; Smith, Jason G (2018) Adenovirus infection of human enteroids reveals interferon sensitivity and preferential infection of goblet cells. J Virol :
Eaton, Keith D; Romine, Perrin E; Goodman, Gary E et al. (2018) Inflammatory Gene Polymorphisms in Lung Cancer Susceptibility. J Thorac Oncol 13:649-659
Bar, Merav; Flowers, Mary E D; Storer, Barry E et al. (2018) Reversal of Low Donor Chimerism after Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion: A Prospective Phase II Multicenter Trial. Biol Blood Marrow Transplant 24:308-313
Gauthier, Jordan; Turtle, Cameron J (2018) Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy. Curr Res Transl Med 66:50-52
Graves, Scott S; Parker, Maura H; Stone, Diane et al. (2018) Anti-Inducible Costimulator Monoclonal Antibody Treatment of Canine Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant 24:50-54
Amundsen, Susan K; Smith, Gerald R (2018) The RecB helicase-nuclease tether mediates Chi hotspot control of RecBCD enzyme. Nucleic Acids Res :
Méndez, Eduardo; Rodriguez, Cristina P; Kao, Michael C et al. (2018) A Phase I Clinical Trial of AZD1775 in Combination with Neoadjuvant Weekly Docetaxel and Cisplatin before Definitive Therapy in Head and Neck Squamous Cell Carcinoma. Clin Cancer Res 24:2740-2748
Buckley, Sarah A; Percival, Mary-Elizabeth; Othus, Megan et al. (2018) A comparison of patients with acute myeloid leukemia and high-risk myelodysplastic syndrome treated on versus off study. Leuk Lymphoma :1-7

Showing the most recent 10 out of 1267 publications